that is key for gilead. some applauded gilead for saying, hey, we need to take this risk to move into a new area where we can grow in an important franchise. a number of analysts coming out and tempering the concern here. certainly it's not a good thing. to your point, if we were sitting here on a day when this deal was still out there, gilead shares would be down. this would be down. people would be talking about either a deal breaker or significant price cut. >> right. >> that is to be sure. but it is still early days for the test. >> right. >> or for the testing, we should say. >> and the big point they did make in the conference call -- >> perhaps a temporary setback is what some are saying. >> the big point they were saying in the conference call, these were patients in the gino type 1 so called in the pharma world. people viewed as the very difficult test group. the people who had already been tested before unsuccessfully coming back and doing this four weeks of treatment. so maybe it should have been

shares of gilead shot up 11% to a new 52-week high. shares have doubled since first announcing its pharmasset purchase. but optimistic early trials of the hepatitis c medicine sent shares of competing drug developers lower. identix fell 11%. achillion and vertex pharmaceuticals were down 5% and 4% respectively. finally, in the commodity market, we saw cocoa, copper and cotton stage decent rallies. the strong jobs data helped the overall commodity picture. with more jobs comes more demand. cocoa supplies from west africa are expected to fall. copper is close to its highest price since september with its 3% rally today, and cotton futures jumped thanks to the jobs report and worries about a flood-damaged crop in australia hurting supplies. and that's tonight's "market focus." >> susie: more than 100 million people are expected to watch the super bowl on sunday, but they're not just tuning in for the football. according to a recent study, 25% of viewers watch the event solely for the commercials. so, advertisers are going all out to make

gilead science on the downside getting crushed. patients in a trial of hepatitis c drug have relapsed. seema mody will have more on this in a minute. decline there down 15%. profits at general mills missed estimates and they cut their full year guidance down $1.53. the stock right now at $38.25. nordstrom earnings, i've been there lately, got this suit there a few months ago. beat their estimates but the stock is down 2%. nonetheless, they warned on margins full year profit forecast was weaker than consensus. now you know where i shop. and for the latest action on the trading floors, let's go to courtney reagan from the nyse. courtney. >> hi, good afternoon, tyler. well, we're watching dow trying to get close to 13,000. we're about 68 points away right now. intel, one of those components in the dow, is moving nicely. take a look at it. we're seeing highs not seen since about december 27, 2007. so more than a four-year high here. the last time that intel was around these levels -- it was up rather i'm sorry 10% since the dow closed

after a sharp rally this year in gilead sciences, the stock plummeted today dropping 14%. investors have been bidding up shares as it continued its $11 billion buyout of phamasset, picking up an experimental hepatitis "c" treatment with big potential. but data today on the medicine indicates some patients taking it relapsed after the treatment ended. those working on alternative hepatitis "c" medicines got a boost from the gilead disappointment. vertex jumped more than 4.5%. merck's stock added 1%. both of their medicine's received approval last year. finally, lin-sanity continues. the excitement around harvard economics graduate and now start new york knick's point guard jeremy lin may have helped get knick games back on time warner cable. time warner had been in a fight with madison square garden over what time warner pays to carry the m.s.g. network. m.s.g. shares continue hitting new highs thanks to the lin- sanity excitement. and time warner cable finished at a seven month high. and that's tonight's market focus. >> susie: no hard landing for china's economy this year

also missing street estimates, came in at 97 cents a share for gilead sciences. it kick started a frenzy in the biotech space. bristol-myers, we can expect investors to discuss gilead's acquisition on the call, some saying there will be more details on the action coming up soon. >> seema mody with the latest there. super bowl xlvi, up next we speak to the chairman of one of the two teams set to take the field. new york giants chief with us next. >>> super bowl xlvi kicks off sunday on nbc. as the new york giants take on the new england patriots, a rematch from the big game four years ago. throughout the day on cnbc, we've pitted new york against boston in the super bowl cities to see which metro area is better for business. the giants and patriots have won three super bowls in their history, so how have the markets performed on the monday following the wins? and who should call wall street -- who should wall street be cheering for? mary thompson is in foxboro, massachusetts. brian shactman at the met life stadium in new jersey. we start with mary. >> maria, wall

you had gilead and bristol-myers buying inhibitex for a 163% premium. is the dealmaking out of control in biotech? >> i don't know if it's out of control. what happens is that big pharma is facing now -- is in the middle of the so-called patent cliff. a lot of their big blockbuster drug that is generated billions of dollars -- they have to look for value somewhere else and this is why when they find exciting biopharmaceutical products -- >> j.j., let me ask it another way, then. i don't blame the seller, right? good for the board of inhibitex getting that kind of a premium? would you pay 163% premium for a company that you wanted to buy? >> i would say that would be unlikely. we'd rather buy products in early stage and pay a limited -- we did two small acquisitions in the past 18 months where we paid $20 million up front. >> and you're looking to do further acquisitions as well this year? >> well, we might. we're always looking at potential small acquisitions. our pipeline is pretty full, as i said earlier. we have five new molecules in the clinic. we'r

profits gilead sciences missed expectations but upbeat results of hep c drug lifting outlook.nd urban outfitters up 6% on an upgrade. they also named incidentally a new ceo. bucking the trend as we head into the weekend, the super bowl weekend, earnings at edward life sciences beat estimates, but the guidance there is disappointing. estee lauder meanwhile also matching estimates, but guidance short of expectations. and wynn resorts, profits up 67%, but investors worried about the feud between ex-ceo steve wynn and a prominent shareholder. down to the nyse and latest from bob pisani. >> thank you, simon. five to one advancing to decl e declinideclin declining stocks. and are you ready for this? strong volume. we could do 4.5 billion shares on the consolidated, maybe even a little more. haven't done that in quite a while. volume, would you believe it? take a look at new highs of the major indices. dow industrials, all we have to do is close above 12,810 to hit a new three-year high. three and a half year high as well that's historic high for the s&p retail index. it's a basket o

you look at gilead and the move in that stock you might say it's a little biotech company what's theh company. to cut off 20% of the market cap you're talking about a huge market cap loss just based on this that you're seeing. general mills sees third quarter 54 to 56 cents below expectation. which had been at 60 cents. recent u.s. volume weakness will affect the results and 2012 full year view has been cut to 2.53 to 2.76. heinz reporting, says here -- you got to watch "squawk box" because it says here that the company best known for ketchup. yeah. yeah. does that help with you this story? >> a little bit. >> okay. so with that in mind that this is a ketchup maker reported quarterly profit of 95 cents a share. excluding items of 10 cents above estimates. the results were helped by strength in emerging markets. >> those little new ketchup packs. have you looked at those. >> what are they? >> you can squeeze it out in a new way and doesn't get all over the place. it's fantastic. >> the packaging? >> the packaging is huge. >> i like smashing it. >> can you tell me the difference betwee

." >> and the possible cocktail with gilad and two drugs with 100% efficacy, if gilead, plus rib ribovarinombination of two drugs, we believe we can combine idx-184 with another potent anti-viral and get the same kind of efficacy. this is going to be a combination game. so, we're looking right now to partner our compound with our experimental medicine with another potent experimental medicine that we believe will give us as much of a chance to be competitive with what we're seeing out there. the other thing that is important to point out hepatitis "c" is a heterogenous disease, within the disease there are 6 to 12 different subtypes and what we're seeing out there doesn't necessarily treat all of the subtypes, so what we're really looking forward to with idx-184 is coming out of the gate with a combination therapy that can address as many patients as possible. >> i'm going to jump in here, ron, and to joe's point a moment ago about it being a very crowded area and there is a lot of competition, do you have any other high-flying drugs out there, you know, things that are going to diversify